RxDoctor Payments Data

Emily Govro, DO

Family Medicine · Hillsboro, MONPI 1588224190

Payments from drug & device makers

$727in general payments, 2019–2025

Across 28 payments — averaging $25.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$155
  • Abiomed$134
  • Novo Nordisk$121
  • Lilly USA, LLC$117
  • AstraZeneca$78
  • Lundbeck LLC$39
  • plus $84 from 4 others

What the payments were for

  • Food & beverage$68995%
  • Education$395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen6$155
Abiomed1$134
Novo Nordisk4$121
Lilly USA, LLC6$117
AstraZeneca5$78
Lundbeck LLC1$39
Pfizer2$29
AbbVie1$22
Boehringer Ingelheim1$17
GSK1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$727 in reported general payments places this provider in the 55th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$46,801
Medicare patients
131
Services billed
543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$87,237
TrulicityDulaglutide48$83,379
OzempicSemaglutide36$69,550
MounjaroTirzepatide40$51,975
Invega SustennaPaliperidone Palmitate13$46,568
JardianceEmpagliflozin25$42,442
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$37,118
XareltoRivaroxaban33$32,431
RybelsusSemaglutide14$23,357
JanuviaSitagliptin Phosphate14$23,192
FarxigaDapagliflozin Propanediol15$19,652
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$16,527
Spiriva HandihalerTiotropium Bromide19$16,089
MyrbetriqMirabegron28$12,837
ArexvyRsvpref3 Antigen/As01e/Pf36$9,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$117$135,35488 claims
Novo NordiskOzempic, Rybelsus$121$92,90750 claims
PfizerEliquis, Abrysvo$29$89,434113 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Breo Ellipta, Incruse Ellipta$15$77,217130 claims
Boehringer IngelheimJardiance$17$42,44225 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$78$33,06852 claims
AbbVieSynthroid$22$1,39427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Hillsboro

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →